Clinical Trial: NAV-1104

Trial Status: Open
Disease Type: Lung
Trial ID NAV-1104
Sponsor ID Navire Pharma

Phase 1 Study of SHP2 Inhibitor BBP-398 in Combination with the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer with a KRAS Mutation

1 Location

Locations

Fairfax Office

Learn More About This Trial

Other Relevant Trials
Trial ID FURMO
Sponsor ID Arri Vent BioPharma

A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations Including Exon 20 Insertion Mutations

1 Location
Trial ID VS-6766-204
Sponsor ID RAMP 204

A Phase 1/2 Study of VS-6766 in Combination with Adagrasib in Patients with KRAS G12C Mutant Non-Small Cell Lung Cancer

1 Location